drugset
drugset / Trial / NCT05029921

A Study of Ustekinumab (STELARA) in Chinese Participants With Moderately to Severely Active Crohn's Disease

NCT05029921 ↗

Phase 4 Completed 182 enrolled Janssen Research & Development, LLC
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the clinical and endoscopic efficacy and safety of ustekinumab in Chinese participants with moderately to severely active Crohn's disease.

Timeline

Start
2021-12-10
Primary completion
2025-05-18
Completion
2025-05-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Ustekinumab Monoclonal antibody 90 mg Intravenous

Indications

Crohn disease